News Roundup / UK Pharma May 2020
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British intensive care units (ICUs), COVID-19 drug trials, biotech deals and market access…
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British intensive care units (ICUs), COVID-19 drug trials, biotech deals and market access…
Mouloud Boukhachab, Pierre Fabre’s managing director for Africa, the Middle East and Turkey, took on the new responsibilities of his current position in March 2020 at the beginning of the…
IFPMA Director General Thomas B. Cueni shares the outcomes of a recent high level pharma industry media briefing on the search for a COVID-19 treatment; highlighting the unprecedented levels of…
Carol Lynch, president of Sandoz US and head of Sandoz North America, recently spoke exclusively to PharmaBoardroom about how her diverse global experiences in innovative biopharma and biosimilars are informing…
Alphamab Oncology and I-Mab Biopharma, two of China’s fastest-growing biotech firms, both bolstered by recent successful IPOs, are increasingly adapting their portfolio strategies to launch products on the large but…
Established in December 2012, in less than a decade, Chinese biotech Junshi Biosciences has already transformed itself into a publicly-listed commercial company with a successful USD 450 million IPO on…
Top recent news from Chinese pharma, including listings on the Hong Kong Stock Exchange, Junshi’s out-licensing of a potential COVID-19 treatment to Lilly, and Ascentage being granted US FDA orphan…
DataArt’s Daniel Piekarz looks at how machine learning and artificial intelligence can play into the important task of drug repurposing, potentially providing solutions to the most pressing healthcare concerns of…
Below we highlight recent news in the Latin America region, focusing on Argentina, Colombia and Chile. Top stories cover the fight against COVID-19, economic uncertainty in the Mercosur region, and…
Accounting for less than two percent of the global pharmaceutical market, the Middle East has long been somewhat overlooked by many drug makers, most of whom seemed more intent on…
Dr Neil Cashman examines the recent news around Biogen’s Alzheimer’s treatment aducanumab, assuages some investor fears, and underlines the treatment’s solid fundamentals and potential. On April 2020, Biogen initiated…
A selection of recent big stories from Chinese pharma, including Novo Nordisk’s updated China strategy, Chinese biotechs’ funding successes, and some significant regulatory approvals. In Q1 2020, China’s regulator…
See our Cookie Privacy Policy Here